Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.65 Million USD | -45.86% |
| 2022 | -14.16 Million USD | 9.96% |
| 2021 | -15.72 Million USD | 40.52% |
| 2020 | -26.44 Million USD | -69.79% |
| 2019 | -15.57 Million USD | -57.09% |
| 2018 | -9.91 Million USD | -47.28% |
| 2017 | -6.73 Million USD | 4.02% |
| 2016 | -7.01 Million USD | 40.12% |
| 2015 | -11.71 Million USD | -102.29% |
| 2014 | -5.78 Million USD | 63.97% |
| 2013 | -16.06 Million USD | -22.75% |
| 2012 | -13.09 Million USD | -70.47% |
| 2011 | -7.67 Million USD | 1.62% |
| 2010 | -7.8 Million USD | -41.41% |
| 2009 | -5.51 Million USD | 8.34% |
| 2008 | -6.02 Million USD | -160.49% |
| 2007 | -2.31 Million USD | 21.26% |
| 2006 | -2.93 Million USD | 9.71% |
| 2005 | -3.25 Million USD | -5.64% |
| 2004 | -3.07 Million USD | -83.98% |
| 2003 | -1.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.3 Million USD | 5.95% |
| 2024 Q1 | -2.45 Million USD | 80.77% |
| 2023 Q3 | -2.01 Million USD | 34.02% |
| 2023 Q1 | -2.78 Million USD | -1038.49% |
| 2023 Q2 | -3.05 Million USD | -9.41% |
| 2023 Q4 | -12.74 Million USD | -533.29% |
| 2023 FY | -20.65 Million USD | -45.86% |
| 2022 FY | -14.16 Million USD | 9.96% |
| 2022 Q3 | -3.88 Million USD | 3.74% |
| 2022 Q4 | -244.9 Thousand USD | 93.69% |
| 2022 Q1 | -6.01 Million USD | -162.42% |
| 2022 Q2 | -4.03 Million USD | 32.97% |
| 2021 Q3 | -4.38 Million USD | -14.9% |
| 2021 Q4 | -2.29 Million USD | 47.7% |
| 2021 Q1 | -5.21 Million USD | -18.39% |
| 2021 Q2 | -3.81 Million USD | 26.91% |
| 2021 FY | -15.72 Million USD | 40.52% |
| 2020 FY | -26.44 Million USD | -69.79% |
| 2020 Q2 | -12.33 Million USD | -137.82% |
| 2020 Q1 | -5.18 Million USD | -44.21% |
| 2020 Q4 | -4.4 Million USD | 1.95% |
| 2020 Q3 | -4.49 Million USD | 63.55% |
| 2019 Q4 | -3.59 Million USD | 6.24% |
| 2019 FY | -15.57 Million USD | -57.09% |
| 2019 Q3 | -3.83 Million USD | 20.18% |
| 2019 Q1 | -3.32 Million USD | -20.69% |
| 2019 Q2 | -4.8 Million USD | -44.52% |
| 2018 FY | -9.91 Million USD | -47.28% |
| 2018 Q2 | -2.28 Million USD | -7.64% |
| 2018 Q4 | -2.75 Million USD | 0.08% |
| 2018 Q3 | -2.75 Million USD | -20.89% |
| 2018 Q1 | -2.11 Million USD | -45.09% |
| 2017 Q2 | -1.22 Million USD | 38.42% |
| 2017 Q1 | -1.98 Million USD | 25.87% |
| 2017 Q4 | -1.46 Million USD | 29.34% |
| 2017 Q3 | -2.06 Million USD | -69.32% |
| 2017 FY | -6.73 Million USD | 4.02% |
| 2016 Q4 | -2.67 Million USD | -36.26% |
| 2016 FY | -7.01 Million USD | 40.12% |
| 2016 Q3 | -1.96 Million USD | -527.93% |
| 2016 Q2 | -312.61 Thousand USD | 84.85% |
| 2016 Q1 | -2.06 Million USD | 7.05% |
| 2015 Q3 | -1.86 Million USD | 70.58% |
| 2015 FY | -11.71 Million USD | -102.29% |
| 2015 Q4 | -2.21 Million USD | -19.09% |
| 2015 Q2 | -6.33 Million USD | -390.07% |
| 2015 Q1 | -1.29 Million USD | -5.66% |
| 2014 Q3 | -1.02 Million USD | 45.69% |
| 2014 FY | -5.78 Million USD | 63.97% |
| 2014 Q1 | -1.64 Million USD | 46.71% |
| 2014 Q2 | -1.89 Million USD | -15.52% |
| 2014 Q4 | -1.22 Million USD | -18.85% |
| 2013 FY | -16.06 Million USD | -22.75% |
| 2013 Q3 | -9.32 Million USD | -349.63% |
| 2013 Q1 | -1.58 Million USD | 20.06% |
| 2013 Q4 | -3.07 Million USD | 66.98% |
| 2013 Q2 | -2.07 Million USD | -30.45% |
| 2012 Q4 | -1.98 Million USD | 22.19% |
| 2012 Q1 | -1.61 Million USD | 16.63% |
| 2012 FY | -13.09 Million USD | -70.47% |
| 2012 Q2 | -6.92 Million USD | -328.52% |
| 2012 Q3 | -2.55 Million USD | 63.11% |
| 2011 Q1 | -1.55 Million USD | 28.24% |
| 2011 Q4 | -1.93 Million USD | -7.31% |
| 2011 Q2 | -2.37 Million USD | -52.23% |
| 2011 FY | -7.67 Million USD | 1.62% |
| 2011 Q3 | -1.8 Million USD | 23.85% |
| 2010 Q2 | -2.01 Million USD | -15.05% |
| 2010 FY | -7.8 Million USD | -41.41% |
| 2010 Q4 | -2.17 Million USD | -15.85% |
| 2010 Q1 | -1.74 Million USD | -41.73% |
| 2010 Q3 | -1.87 Million USD | 6.72% |
| 2009 Q4 | -1.23 Million USD | 14.21% |
| 2009 FY | -5.51 Million USD | 8.34% |
| 2009 Q1 | -1.98 Million USD | 33.92% |
| 2009 Q2 | -869.04 Thousand USD | 56.12% |
| 2009 Q3 | -1.43 Million USD | -65.35% |
| 2008 Q3 | -1.13 Million USD | -3.93% |
| 2008 Q1 | -791.63 Thousand USD | -15.26% |
| 2008 FY | -6.02 Million USD | -160.49% |
| 2008 Q4 | -2.99 Million USD | -163.32% |
| 2008 Q2 | -1.09 Million USD | -38.34% |
| 2007 Q2 | -591.72 Thousand USD | -9.34% |
| 2007 Q1 | -541.15 Thousand USD | 25.2% |
| 2007 Q4 | -686.83 Thousand USD | -40.94% |
| 2007 Q3 | -487.33 Thousand USD | 17.64% |
| 2007 FY | -2.31 Million USD | 21.26% |
| 2006 Q2 | -796.71 Thousand USD | 6.97% |
| 2006 Q4 | -723.45 Thousand USD | -29.38% |
| 2006 Q3 | -559.16 Thousand USD | 29.82% |
| 2006 FY | -2.93 Million USD | 9.71% |
| 2006 Q1 | -856.38 Thousand USD | -12.48% |
| 2005 Q3 | -751.17 Thousand USD | 13.92% |
| 2005 Q1 | -866.13 Thousand USD | 31.21% |
| 2005 FY | -3.25 Million USD | -5.64% |
| 2005 Q2 | -872.68 Thousand USD | -0.76% |
| 2005 Q4 | -761.39 Thousand USD | -1.36% |
| 2004 Q2 | -667.66 Thousand USD | -24.23% |
| 2004 Q1 | -537.44 Thousand USD | 14.35% |
| 2004 Q3 | -613.77 Thousand USD | 8.07% |
| 2004 Q4 | -1.25 Million USD | -105.13% |
| 2004 FY | -3.07 Million USD | -83.98% |
| 2003 Q2 | -437.31 Thousand USD | -106.83% |
| 2003 Q4 | -627.47 Thousand USD | -58.16% |
| 2003 FY | -1.67 Million USD | 0.0% |
| 2003 Q3 | -396.72 Thousand USD | 9.28% |
| 2003 Q1 | -211.44 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 28.68% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -139.293% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 70.084% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 57.688% |
| Azitra, Inc. | -11.28 Million USD | -83.057% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -170.576% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -179.858% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 29.3% |
| CEL-SCI Corporation | -32.36 Million USD | 36.18% |
| iBio, Inc. | -24.9 Million USD | 17.069% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 3.864% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -4.465% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 9.965% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -36.098% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -114.271% |
| NanoViricides, Inc. | -8.29 Million USD | -149.04% |
| BiomX Inc. | -26.16 Million USD | 21.068% |
| BiomX Inc. | -26.16 Million USD | 21.068% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 348.505% |
| Palatin Technologies, Inc. | -29.73 Million USD | 30.537% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 54.319% |